conflits d’intérêt astra-zeneca, bms, msd, novartis, pfizer, daiichi-sankyo, servier,
DESCRIPTION
Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot. Nord. Essonne. Côte-d ’ Or. Haute-Savoie. Haute-Garonne. Demographic characteristics. 200 patients analysed. Côte-d ’ Or : 29 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/1.jpg)
Agrément FMC N° 100 437
Conflits d’intérêt
Astra-Zeneca, BMS, MSD, Novartis,
Pfizer, Daiichi-Sankyo, Servier,
CRAM, AFSSAPS, ARH
Région de Bourgogne
Clos Vougeot
![Page 2: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/2.jpg)
![Page 3: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/3.jpg)
Nord
Haute-Garonne
Haute-Savoie
Côte-d’Or
Essonne
Popul.millions
Areakm2
Densityinha/km2
NORD 2,5 5 743 447Essonne 1,2 1 804 668Hte Garonne
1,2 6 309 193
Hte Savoie
0,7 4 388 163
Côted’Or
0,5 8 763 60
# 6
![Page 4: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/4.jpg)
Côte-d’Or : 29Haute-Garonne : 39Nord : 57Haute-Savoie : 37Essonne : 38
Almost 3/4 of males : 72,5 % male
Demographic characteristics
200 patients analysed
![Page 5: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/5.jpg)
– Mean age : 63,3 yrs with regional differences : 69,4 yrs in Côte-d’Or 60,0 yrs in Essonne
Demographic characteristics
– More than half of patients retired (54 %), with regional differences
74,1 % in Côte-d’Or 40,5 % in Essonne
![Page 6: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/6.jpg)
– Hypertension : 43,5 %– Diabetes : 21,4 %– Active smoking : 44,9 %– Mean weight : 77 kg– BMI ≥ 30 : 20,8 %
Risk factors and medical history
– CAD known prior to admission : 19,7 %
![Page 7: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/7.jpg)
– In 3/4 of cases (71,1 %), chest pain triggers a phone call
– Emergency number 15 : only in 49 % of cases
First aid
– Chest pain reported in 93,9 % of cases
– Emergency ambulance (SAMU/SMUR) is the 1st medical contact in less than 50 % of cases
![Page 8: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/8.jpg)
• Patients without reperfusion : older Half are female ¼ are employed
Revascularisation modesFibrinolysis Primary PCI no reperfusion p
Population
AgeFemale (%)Occupation (%)
EmployedUnemployed
Retired
22 %
63 ± 1323 %
445,1
51,3
64 %
62 ± 1324 %
418,1
50,5
14 %
70 ± 1250 %
224,3
73,9
< 0,001
< 0,01< 0,02
0,32
![Page 9: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/9.jpg)
Widimsky P et al, Eur Heart J 2010; 31:943-57.
Primary PCI Thrombolysis No reperfusion
France
64
22
14
![Page 10: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/10.jpg)
Patients referred directly to an interventional cardiology unit
Preferred strategy is direct hospitalisation to cath-lab 64 % as an average
70,2 % if patient referred by medical ambulance
1er call Admission P PCI
20 min33 min 54 min 43 min
97 min
symptom onset
FMC
![Page 11: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/11.jpg)
Symptom onset
Patients referred to peripheral centres
Admission to the cath lab P PCI
163 min
227 min204 min
• Mean delay was more than double
FMC
![Page 12: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/12.jpg)
Effects of numbers of actors
4,25,5
9,7
% h
ospi
tal m
orta
lity
Nr of actors
![Page 13: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/13.jpg)
![Page 14: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/14.jpg)
USIK
1995
2152
patients
373 centres
1536 STEMI
Population
USIC
2000
2320
patients
369 centres
1844 STEMI
FAST-MI
2005
3059
patients
223 centres
1611 STEMI
FAST-MI
2010
3069
patients
213 centres
1716 STEMI
![Page 15: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/15.jpg)
FAST-MI 2010
213 centres Inclusion from October
2010 4169 patients included 3079 patients included
during the first month
![Page 16: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/16.jpg)
Proportion of STEMI patients from 1995 to 2010
Generalised use of troponin
measurement
![Page 17: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/17.jpg)
Admission diagnosis: STEMI vs NSTEMI
![Page 18: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/18.jpg)
First place of arrival
STEMI
NSTEMI38+11.5% call SAMU first21% call their GP first 19% go to ER 29+8% call SAMU first
27% call their GP first19% go to ER
![Page 19: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/19.jpg)
![Page 20: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/20.jpg)
Increased % of younger women
![Page 21: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/21.jpg)
Time to first call in STEMI patients
% of patients calling ≤60 min from onset
![Page 22: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/22.jpg)
Use of the SAMU/firebrigade in STEMI
Use of the SAMU/ FB in patients with STEMI
2005 2010
![Page 23: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/23.jpg)
Reperfusion therapy in STEMI
![Page 24: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/24.jpg)
STEMI: early mortality according to use and type of reperfusion therapy
2.12.6
- 48 % - 74 % - 70 %
![Page 25: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/25.jpg)
30-day mortality: STEMI & NSTEMI
5 ?
![Page 26: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/26.jpg)
![Page 27: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/27.jpg)
Mortality according to timing of PCI after thrombolysis
FAST-MI 2005
No PCI PCI ≤128 minutes PCI 129-220 minutes PCI > 220 minutes
Systematic pharmaco-invasive
Rescue or symptom-driven PCI
All patients with PCI after lysis
![Page 28: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/28.jpg)
Genetic determinants of clopidogrel response and clinical events in FAST-MI 2005
Simon et al. NEJM 2009
FAST-MI registry
2,208 patients withAMI, followed for one year
Number of CYP2C19 loss-of-function alleles
![Page 29: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/29.jpg)
Early prescription of statins is associated with lower risk of developing acute AF
Danchin et al. Heart 2010
% of patients developing AF
![Page 30: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/30.jpg)
LMWH vs UFH in elderly patients
Puymirat et al. Int J Cardiol 2012
Survival in propensity score-matched cohorts
![Page 31: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/31.jpg)
Standard vs loading dose of clopidogrel in elderly patients: FAST-MI 2005
Puymirat et al. Am J Cardiol 2011
One-year event-free survival
Adjusted HR (95%CI): 0.92 (0.68-1.25)
![Page 32: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/32.jpg)
Conclusion
Periodical surveys are a unique tool to document the evolution of management and outcomes in patients admitted with AMI.
Both the organisation of care and acute management have considerably evolved in the past 15 years.
![Page 33: Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier,](https://reader035.vdocuments.pub/reader035/viewer/2022062800/56814035550346895dab9acb/html5/thumbnails/33.jpg)
Conclusion
Early mortality has impressively decreased, both for STEMI and NSTEMI patients.
The improved outcome in AMI patients is not related to one single therapeutic measure, but rather results from an improvement in the overall process of care.
There are many lessons to be learned from such surveys.